Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

BioNTech SE (BNTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow BioNTech's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
86.81 +0.64    +0.74%
21:00:01 - Closed. Currency in USD ( Disclaimer )
After Hours
86.81
0.00
0.00%
21:24:39 - Real-time Data
  • Volume: 1,203,492
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 85.64 - 87.59
Type:  Equity
Market:  United States
BioNTech 86.81 +0.64 +0.74%

BioNTech Company Profile

 
Read the BioNTech SE company profile to learn more about the business and the management team. View Biontech Se facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

5700

Equity Type

ORD

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Contact Information

Address An der Goldgrube 12
Mainz, 55131
Germany
Phone 49 6131 9084 0
Fax 49 6131 9084 390

Top Executives

Name Age Since Title
Helmut W. Jeggle 51 2008 Independent Supervisory Board Chairman
Ulrich Wandschneider 61 2018 Independent Deputy Chairman Supervisory Board
Michael Motschmann 66 2008 Independent Supervisory Board Member
Anja Morawietz 46 2022 Supervisory Board Member
Rudolf Staudigl 69 2022 Supervisory Board Member
Nicola Blackwood 45 2023 Member of Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BNTX Price Commentary

Write your thoughts about BioNTech SE
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ali Atat
Ali Atat Jan 21, 2022 7:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Financial figures state 12$ per share per sept quarter… Dec21 quarter 8$ per share per quarter… simple math shows this stock is worth at least 300$.
Ali Atat
Ali Atat Jan 20, 2022 8:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Think long, this is 270Euro value stock
Ali Atat
Ali Atat Jan 19, 2022 8:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The drop in price has no logical explanation! This company is producing best vaccine that will long live with humanity. Its fair value today is 270 Euro! Investors are throwing away a good opportunity by selling!
Shums Cassim
Shums Cassim Nov 07, 2021 0:27
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Price crash due to fake news of Pfizer CEO arrest? Huge buy opportunity right now.
Neja Abdualkerm
Neja Abdualkerm Oct 23, 2021 18:11
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We are Habesha kemis traditional dresses shop
Noel Tan
Noel Tan Aug 23, 2021 13:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big buy now!
Daniel Chang
Daniel Chang Aug 13, 2021 7:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news FDA had authorised extra dose vaccine!
John HZ
Bench Aug 13, 2021 7:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not quite! Authorisation is restricted to the severely immunocompromised
Cathy Huynh
Cathy Huynh Aug 12, 2021 18:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy?
Daniel Chang
Daniel Chang Aug 12, 2021 7:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
3rd fose covid vaccine
Daniel Chang
Daniel Chang Aug 12, 2021 7:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
latest news. FDA reported to give full approval of Pfizer covid vaccine by Labor Day.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email